Recent Updates
Recently added Catalysts
MGNX Positive Sentiment Score: 70/100

MacroGenics to Participate in Upcoming Investor Conferences

Key Takeaway: MacroGenics, Inc. has announced its participation in two upcoming investor conferences in March 2023. The company's CEO, Scott Koenig, M.D., Ph.D., will be involved in key discussions at the TD Cowen Annual Health Care Conference and the Barclays Global Healthcare Conference. The events will feature one-on-one meetings and discussions relevant to the oncology sector. Additionally, MacroGenics will provide webcasts of the presentations on their website for investors to access.

Market Sentiment Analysis

POSITIVE FACTORS

  • MacroGenics is engaging with investors through multiple conferences.
  • Participation in health industry panels reflects confidence in their innovations.
  • The company is well-positioned to showcase its advancements in cancer therapeutics.

Full Press Release Details

ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2023:
TD Cowen’s 43rd Annual Health Care Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the GI/GU Oncology Corporate Panel Discussion on Tuesday, March 7, 2023, at 12:50 pm ET.  MacroGenics’ management will also participate in one-on-one meetings; and
Barclays Global Healthcare Conference (Miami). Scott Koenig, M.D., Ph.D. will participate in a fireside chat on Tuesday, March 14, 2023, at 9:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.
A webcast of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain an archived replay of these webcasts on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Tags

Antibody-drug Conjugate
CONFERENCE PRESENTATION

Frequently Asked Questions

When is MacroGenics presenting at the TD Cowen Health Care Conference?

MacroGenics will present on March 7, 2023, at 12:50 pm ET.

What event will MacroGenics' CEO participate in on March 14?

Scott Koenig will participate in a fireside chat at the Barclays Conference.

How long will the webcasts be available on MacroGenics' site?

The webcasts will be available for 30 days after the events.

What does MacroGenics focus on developing?

MacroGenics specializes in innovative antibody-based therapeutics for cancer.

Where can I find more information about MacroGenics?

More information is available on their website at www.macrogenics.com.

Last updated: Mar 2, 2023